BLACKROCK HEALTH SCIENCES (BME) Fundamental Analysis & Valuation

NYSE:BME • US09250W1071

Current stock price

38.79 USD
+0.3 (+0.78%)
Last:

This BME fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. BME Profitability Analysis

1.1 Basic Checks

  • In the past year BME was profitable.
  • BME had a positive operating cash flow in the past year.
  • BME had positive earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: BME reported negative operating cash flow in multiple years.
BME Yearly Net Income VS EBIT VS OCF VS FCFBME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

1.2 Ratios

  • The last Return On Invested Capital (0.24%) for BME is above the 3 year average (0.21%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 13.59%
ROE 13.63%
ROIC 0.24%
ROA(3y)7.02%
ROA(5y)5.16%
ROE(3y)7.06%
ROE(5y)5.24%
ROIC(3y)0.21%
ROIC(5y)0.17%
BME Yearly ROA, ROE, ROICBME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 15

1.3 Margins

  • In the last couple of years the Profit Margin of BME has declined.
  • BME's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 22.48%
PM (TTM) 1000.52%
GM 100%
OM growth 3Y3.91%
OM growth 5Y75.67%
PM growth 3YN/A
PM growth 5Y-8.11%
GM growth 3YN/A
GM growth 5YN/A
BME Yearly Profit, Operating, Gross MarginsBME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 1K 1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BME Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, BME has about the same amount of shares outstanding.
  • Compared to 5 years ago, BME has more shares outstanding
  • BME has a worse debt/assets ratio than last year.
BME Yearly Shares OutstandingBME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
BME Yearly Total Debt VS Total AssetsBME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 164.86 indicates that BME is not in any danger for bankruptcy at the moment.
  • The Debt to FCF ratio of BME is 0.02, which is an excellent value as it means it would take BME, only 0.02 years of fcf income to pay off all of its debts.
  • A Debt/Equity ratio of 0.00 indicates that BME is not too dependend on debt financing.
  • Although BME's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.02
Altman-Z 164.86
ROIC/WACCN/A
WACCN/A
BME Yearly LT Debt VS Equity VS FCFBME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 0.23 indicates that BME may have some problems paying its short term obligations.
  • A Quick Ratio of 0.23 indicates that BME may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.23
Quick Ratio 0.23
BME Yearly Current Assets VS Current LiabilitesBME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. BME Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 269.57% over the past year.
  • BME shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -2.30% yearly.
  • BME shows a small growth in Revenue. In the last year, the Revenue has grown by 2.25%.
  • BME shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.11% yearly.
EPS 1Y (TTM)269.57%
EPS 3YN/A
EPS 5Y-2.3%
EPS Q2Q%468.64%
Revenue 1Y (TTM)2.25%
Revenue growth 3Y0.04%
Revenue growth 5Y8.11%
Sales Q2Q%7.69%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BME Yearly Revenue VS EstimatesBME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

More info and screens

Find the best growth stocksShow best growing peers

2

4. BME Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 6.52, the valuation of BME can be described as very cheap.
  • BME is valuated cheaply when we compare the Price/Earnings ratio to 25.60, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 6.52
Fwd PE N/A
BME Price Earnings VS Forward Price EarningsBME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF 9.11
EV/EBITDA N/A
BME Per share dataBME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. BME Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 7.65%, BME is a good candidate for dividend investing.
  • BME's Dividend Yield is rather good when compared to the S&P500 average which is at 1.88.
Industry RankSector Rank
Dividend Yield 7.65%

5.2 History

  • On average, the dividend of BME grows each year by 6.99%, which is quite nice.
  • BME has been paying a dividend for at least 10 years, so it has a reliable track record.
  • BME has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)6.99%
Div Incr Years1
Div Non Decr Years10
BME Yearly Dividends per shareBME Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3

5.3 Sustainability

  • BME pays out 52.94% of its income as dividend. This is a bit on the high side, but may be sustainable.
  • The Dividend Rate of BME has been growing, while earnings will be declining. This means the dividend growth is most likely not sustainable.
DP52.94%
EPS Next 2YN/A
EPS Next 3YN/A
BME Yearly Income VS Free CF VS DividendBME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M
BME Dividend Payout.BME Dividend Payout, showing the Payout Ratio.BME Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BME Fundamentals: All Metrics, Ratios and Statistics

BLACKROCK HEALTH SCIENCES

NYSE:BME (4/2/2026, 8:10:11 PM)

38.79

+0.3 (+0.78%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)03-05
Earnings (Next)N/A
Inst Owners21.62%
Inst Owner Change136.17%
Ins Owners0%
Ins Owner Change0%
Market Cap501.17M
Revenue(TTM)7.74M
Net Income(TTM)77.44M
Analysts0
Price TargetN/A
Short Float %0.52%
Short Ratio1.63
Dividend
Industry RankSector Rank
Dividend Yield 7.65%
Yearly Dividend3.15
Dividend Growth(5Y)6.99%
DP52.94%
Div Incr Years1
Div Non Decr Years10
Ex-Date06-15
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 6.52
Fwd PE N/A
P/S 64.75
P/FCF 9.11
P/OCF 9.11
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)5.95
EY15.34%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)4.26
FCFY10.97%
OCF(TTM)4.26
OCFY10.97%
SpS0.6
BVpS43.98
TBVpS43.98
PEG (NY)N/A
PEG (5Y)N/A
Graham Number76.73
Profitability
Industry RankSector Rank
ROA 13.59%
ROE 13.63%
ROCE 0.31%
ROIC 0.24%
ROICexc 0.24%
ROICexgc 0.24%
OM 22.48%
PM (TTM) 1000.52%
GM 100%
FCFM 710.59%
ROA(3y)7.02%
ROA(5y)5.16%
ROE(3y)7.06%
ROE(5y)5.24%
ROIC(3y)0.21%
ROIC(5y)0.17%
ROICexc(3y)0.21%
ROICexc(5y)0.17%
ROICexgc(3y)0.21%
ROICexgc(5y)0.17%
ROCE(3y)0.27%
ROCE(5y)0.21%
ROICexgc growth 3Y6.11%
ROICexgc growth 5Y88.89%
ROICexc growth 3Y6.11%
ROICexc growth 5Y88.89%
OM growth 3Y3.91%
OM growth 5Y75.67%
PM growth 3YN/A
PM growth 5Y-8.11%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.02
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 250
Cash Conversion N/A
Profit Quality 71.02%
Current Ratio 0.23
Quick Ratio 0.23
Altman-Z 164.86
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)172.8%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)269.57%
EPS 3YN/A
EPS 5Y-2.3%
EPS Q2Q%468.64%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.25%
Revenue growth 3Y0.04%
Revenue growth 5Y8.11%
Sales Q2Q%7.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y87.1%
EBIT growth 3Y3.95%
EBIT growth 5Y89.93%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.67%
OCF growth 3YN/A
OCF growth 5YN/A

BLACKROCK HEALTH SCIENCES / BME Fundamental Analysis FAQ

What is the fundamental rating for BME stock?

ChartMill assigns a fundamental rating of 3 / 10 to BME.


Can you provide the valuation status for BLACKROCK HEALTH SCIENCES?

ChartMill assigns a valuation rating of 2 / 10 to BLACKROCK HEALTH SCIENCES (BME). This can be considered as Overvalued.


Can you provide the profitability details for BLACKROCK HEALTH SCIENCES?

BLACKROCK HEALTH SCIENCES (BME) has a profitability rating of 2 / 10.


How financially healthy is BLACKROCK HEALTH SCIENCES?

The financial health rating of BLACKROCK HEALTH SCIENCES (BME) is 3 / 10.